Galderma Group AG

Galderma Group AG’s shares surged 61 % in a year, outpacing Switzerland’s SMI thanks to FDA approval of Restylane Contour and strong investor sentiment—making it a top pick for growth‑focused investors.

Galderma Group AG’s 3% share rise boosts SMI, showing its strong dermatology portfolio and investor confidence—key for Swiss market gains.

Galderma’s new Sculptra & Restylane trials show lasting volume boost for menopausal & weight‑loss patients, while its ALASTIN Signature Practice rollout aims to elevate peri‑procedural care in the US.

Galderma’s Sculptra gains EU MDR approval, expanding into new body areas and boosting investor confidence with a S&P BBB rating upgrade, positioning it for growth in the booming aesthetics market.

Galderma Group AG reported record first quarter net sales of $1.129 billion, exceeding expectations and solidifying its position as a leader in the dermatology category.

Galderma Group AG exceeded expectations with a 5.4% increase in sales for the first quarter of 2025, driven by strong product demand and new launches, including the “Scratch Resistance” campaign for NEMLUVIO.